Nuvation Bio Inc. Operating Lease Liability
Nuvation Bio Inc. (NUVB) had Operating Lease Liability of $3.63 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-06
- 2026-06-30: Operating Lease, Liability $3.63M.
- 2026-03-31: Operating Lease, Liability $4.04M.
- 2025-12-31: Operating Lease, Liability $4.42M.
- 2025-09-30: Operating Lease, Liability $4.84M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $3.63M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $4.04M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $4.42M 10-K · filed 2026-03-02 |
| 2025-09-30 | $4.84M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $5.21M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $5.73M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $2.63M 10-K · filed 2025-03-06 |
| 2024-09-30 | $2.77M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $3.05M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $3.53M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $4.01M 10-K · filed 2024-02-29 |
| 2023-09-30 | $4.46M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $3.68M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $3.97M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $4.26M 10-K · filed 2023-03-15 |
| 2022-09-30 | $4.47M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $4.69M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $2.79M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $3.06M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |